MedTrace Logo

Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy

NCT03580941 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2020-06-02

No results posted yet for this study

Summary

Haemolytic uremic syndrome (HUS) is defined by the presence of the classic triad of non-immune microangiopathic hemolytic anemia (negative direct Coombs), thrombocytopenia and acute renal failure. Histological lesions of HUS are characterized by a systemic thrombotic microangiopathy (TMA), which mainly affects the renal vessels, with wall thickening, thrombosis and obstruction of the vascular lumen. Atypical HUS (aHUS) is a subtype of HUS in the TMA phenomena that results from the loss of regulation of the alternative complement pathway on cell surfaces and is generally considered to be from a genetic cause. Approximately 10% of HUS cases are classified as atypical HUS, which are associated with a more adverse prognosis, with a mortality rate up to 25% and progression to end stage renal disease in more than 50% of cases.

Conditions

  • Hemolytic-Uremic Syndrome

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia

    lead OTHER

Principal Investigators

  • Jose Rojas, MD. Msc · Gestion Salud

Eligibility

Min Age
14 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-15
Primary Completion
2020-08-30
Completion
2020-11-30

Countries

  • Colombia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03580941 on ClinicalTrials.gov